All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-01-17T10:48:39.000Z

What is the impact of dexamethasone dose strength on outcomes in NDMM?

Jan 17, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in newly diagnosed MM.

Bookmark this article

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Rahul Banerjee, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, What is the impact of dexamethasone dose strength on outcomes in newly diagnosed multiple myeloma? 

What is the impact of dexamethasone dose strength on outcomes in NDMM?

Banerjee discusses the toxicity profile of dexamethasone in patients with newly diagnosed multiple myeloma treated with a standard dose of ~40mg weekly. He then explores the impact of reducing dexamethasone dose strength on incidence and patient outcomes, highlighting both the frequency of adverse events and differences in efficacy outcomes. He concludes by explaining the implications of this data on future dexamethasone use and how to determine the optimal initial dose strength. 

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox